tradingkey.logo

Icecure Medical Ltd

ICCM
查看詳細走勢圖
0.675USD
+0.010+1.52%
收盤 12/19, 16:00美東報價延遲15分鐘
46.54M總市值
虧損本益比TTM

Icecure Medical Ltd

0.675
+0.010+1.52%
盤中分時
1分
30分
1小時
日k
週k
月k
日k

今天

+1.52%

5天

+1.61%

1月

+3.99%

6月

-29.05%

今年開始到現在

-38.65%

1年

-39.74%

查看詳細走勢圖

TradingKey Icecure Medical Ltd股票評分

單位: USD 更新時間: 2025-12-19

操作建議

Icecure Medical Ltd當前公司基本面數據相對非常健康,增長潛力較大。當前估值合理,在醫療設備與耗材行業排名116/208位。機構持股佔比低,近一個月多位分析師給出公司評級為買入。最高目標價3.12。中期看,股價處於下降通道。近一個月,市場表現一般,但公司基本面和技術面得分較高。目前股價在壓力位和支撐位之間,可以做區間波段操作。

Icecure Medical Ltd評分

相關信息

行業排名
116 / 208
全市場排名
274 / 4582
所屬行業
醫療設備與耗材

壓力支撐

由於公司未披露,未能獲取相關數據

多維評測

本期評分
上期評分

分析師目標

基於 2 分析師
買入
評級
3.125
目標均價
+356.60%
漲幅空間
數據免責聲明:分析師評級與目標價由LSEG提供,僅供參考,不應當作投資建議

Icecure Medical Ltd亮點

亮點風險
Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
業績增長期
公司處於發展階段,最新年度總收入3.29M美元
估值高估
公司最新PE估值-2.60,處於3年歷史高位
機構減倉
最新機構持股241.02K股,環比減少18.19%
肯·費雪持倉
明星投資者肯·費雪持倉,最新持倉0.00股
活躍度增加
近期活躍度增加,過去20天平均換手率0.36

Icecure Medical Ltd新聞

即將為您帶來更多新聞,敬請期待。 。 。

財務指標

每股收益

由於公司未披露,未能獲取相關數據

營業總收入

由於公司未披露,未能獲取相關數據

Icecure Medical Ltd簡介

Icecure Medical Ltd is an Israel-based company that is engaged in the healthcare sector. The Company operates as commercial stage medical device company focusing on the research, development and marketing of cryoablation systems, disposables and technologies based on liquid nitrogen, or LN2, for treating tumors. Cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in breast, lungs, kidneys, bones and other indications. Company's lead product is ProSense system, a single probe system, but in addition the Company developed an additional multi probe system that is expected to have the ability to freeze several tumors simultaneously or larger tumors, named MultiSense system, which has not yet been commercialized.
公司代碼ICCM
公司Icecure Medical Ltd
CEOShamir (Eyal)
網址https://icecure-medical.com/

常見問題

Icecure Medical Ltd(ICCM)的當前股價是多少?

Icecure Medical Ltd(ICCM)的當前股價是 0.675。

Icecure Medical Ltd 的股票代碼是什麼?

Icecure Medical Ltd的股票代碼是ICCM。

Icecure Medical Ltd股票的52週最高點是多少?

Icecure Medical Ltd股票的52週最高點是1.660。

Icecure Medical Ltd股票的52週最低點是多少?

Icecure Medical Ltd股票的52週最低點是0.590。

Icecure Medical Ltd的市值是多少?

Icecure Medical Ltd的市值是46.54M。

Icecure Medical Ltd的淨利潤是多少?

Icecure Medical Ltd的淨利潤為-15.32M。

現在Icecure Medical Ltd(ICCM)的股票是買入、持有還是賣出?

根據分析師評級,Icecure Medical Ltd(ICCM)的總體評級為買入,目標價格為3.125。

Icecure Medical Ltd(ICCM)股票的每股收益(EPS TTM)是多少

Icecure Medical Ltd(ICCM)股票的每股收益(EPS TTM)是-0.259。
KeyAI